COMPOSITIONS COMPRISING BACTERIAL STRAINS
The invention provides compositions comprising bacterial strains for treating and preventing cancer.
1 .- 30 . (canceled)
31 . A method of treating a non-immunogenic cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition that comprises a bacterial strain of the species Enterococcus gallinarum comprising a plasmid with at least 93% sequence identity to the sequence of SEQ ID NO: 4, wherein said administering is sufficient to treat the non-immunogenic cancer.
32 . The method of claim 31 , wherein said non-immunogenic cancer is a lung cancer.
33 . The method of claim 32 , wherein said lung cancer is non-small-cell lung carcinoma or small-cell lung carcinoma.
34 . The method of claim 31 , wherein said non-immunogenic cancer is a breast cancer.
35 . The method of claim 34 , wherein said breast cancer is mammary carcinoma or stage IV breast cancer.
36 . The method of claim 31 , wherein said non-immunogenic cancer is a liver cancer.
37 . The method of claim 36 , wherein said liver cancer is hepatocellular carcinoma.
38 . The method of claim 31 , wherein said non-immunogenic cancer is a colon cancer.
39 . The method of claim 38 , wherein said colon cancer is colorectal adenocarcinoma.
40 . The method of claim 31 , wherein said pharmaceutical composition comprises from about 1×10 6 to about 1×10 11 colony forming units (CFU) of said bacterial strain.
41 . The method of claim 31 , wherein said pharmaceutical composition comprises from about 1×10 6 to about 1×10 11 colony forming units per gram (CFU/g) of said bacterial strain with respect to a total weight of said pharmaceutical composition.
42 . The method of claim 31 , wherein said subject is human.
43 . The method of claim 31 , wherein said a bacterial strain comprises a plasmid with at least 95% sequence identity to the sequence of SEQ ID NO: 4.
44 . The method of claim 31 , wherein said a bacterial strain comprises a plasmid with at least 98% sequence identity to the sequence of SEQ ID NO: 4
45 . The method of claim 31 , wherein said a bacterial strain comprises a plasmid with at least 99% sequence identity to the sequence of SEQ ID NO: 4.
46 . The method of claim 31 , wherein said a bacterial strain is the Enterococcus gallinarum strain deposited under accession number NCIMB 42488, a derivative thereof, or a biotype thereof.
47 . The method of claim 46 , wherein said biotype comprises a bacterial strain that has the carbohydrate fermentation profile as the bacterial strain deposited under accession number NCIMB 42488.
48 . The method of claim 47 , wherein said carbohydrate fermentation profile comprises: (i) a positive fermentation of at least one of: L-arabinose and D-xylose; and (ii) an intermediate fermentation of Methyl-αD-glycopyranoside.
49 . The method of claim 31 , wherein said pharmaceutical composition comprises only de minimis or biologically irrelevant amounts of other bacterial strains.
50 . The method of claim 31 , wherein said pharmaceutical composition comprises the bacterial strain as part of a microbial consortium.